Healthcare Industry News: S.A.
News Release - March 31, 2008
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
NEW YORK--(HSMN NewsFeed)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvaS.A.in, the active ingredient in Lipitor, reversing the lower court decision. The enantiomer patent expires in July 2010.The patent was challenged jointly by generic companies Laboratorios Cinfa S.A., Kern Pharma S.L., LaboratorioS.A.ter S.A. and Laboratorios Belmac S.A., and is one of four separate challenges to the enantiomer patent by generic companies in S.A.n. Lipitor is sold in S.A.n under the brand names Zarator and Cardyl. "This iS.A.victory not only for Pfizer, but for all innovators pursuing high-risk medical discoverieS.A.d for the patients who benefit from those discoveries," said Pfizer Senior Vice President and Associate General Counsel Peter C. Richardson. Cinfa, Kern, Alter and Belmac can seek to appeal the decision to the Supreme Court of S.A.n.
Source: Pfizer
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!